Clinical Trial Detail

NCT ID NCT01670877
Title Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Neratinib

Neratinib + Trastuzumab

Fulvestrant + Neratinib + Trastuzumab

Fulvestrant + Neratinib

Age Groups: adult senior

Additional content available in CKB BOOST